Lum B - Search Results

1

Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.

Denlinger CS, Blanchard R, Xu L, Bernaards C, Litwin S, Spittle C, Berg DJ, McLaughlin S, Redlinger M, Dorr A, Hambleton J, Holden S, Kearns A, Kenkare-Mitra S, Lum B, Meropol NJ, O'Dwyer PJ. Denlinger CS, et al. Among authors: lum b. Cancer Chemother Pharmacol. 2009 Dec;65(1):97-105. doi: 10.1007/s00280-009-1008-7. Epub 2009 May 5. Cancer Chemother Pharmacol. 2009. PMID: 19415281 Free PMC article. Clinical Trial.

2

Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys.

Xu L, Zuch CL, Lin YS, Modi NB, Lum BL. Xu L, et al. Among authors: lum bl. Cancer Chemother Pharmacol. 2008 Apr;61(4):607-14. doi: 10.1007/s00280-007-0513-9. Epub 2007 Jun 5. Cancer Chemother Pharmacol. 2008. PMID: 17549476

3

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Lu JF, et al. Among authors: lum b. Cancer Chemother Pharmacol. 2008 Oct;62(5):779-86. doi: 10.1007/s00280-007-0664-8. Epub 2008 Jan 19. Cancer Chemother Pharmacol. 2008. PMID: 18205003

4

A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma.

Advani R, Peethambaram P, Lum BL, Fisher GA, Hartmann L, Long HJ, Halsey J, Holmlund JT, Dorr A, Sikic BI. Advani R, et al. Cancer. 2004 Jan 15;100(2):321-6. doi: 10.1002/cncr.11909. Cancer. 2004. PMID: 14716767 Free article. Clinical Trial.

5

Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.

Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS. Herbst RS, et al. J Clin Oncol. 2010 Jun 10;28(17):2839-46. doi: 10.1200/JCO.2009.25.1991. Epub 2010 May 10. J Clin Oncol. 2010. PMID: 20458040 Clinical Trial.

6

Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.

Garg A, Quartino A, Li J, Jin J, Wada DR, Li H, Cortés J, McNally V, Ross G, Visich J, Lum B. Garg A, et al. Among authors: lum b. Cancer Chemother Pharmacol. 2014 Oct;74(4):819-29. doi: 10.1007/s00280-014-2560-3. Epub 2014 Aug 14. Cancer Chemother Pharmacol. 2014. PMID: 25119184

7

Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study.

Xu N, Redfern CH, Gordon M, Eppler S, Lum BL, Trudeau C. Xu N, et al. Cancer Chemother Pharmacol. 2014 Dec;74(6):1251-60. doi: 10.1007/s00280-014-2603-9. Epub 2014 Oct 26. Cancer Chemother Pharmacol. 2014. PMID: 25344761 Free PMC article. Clinical Trial.

8

Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer.

Cosson VF, Ng VW, Lehle M, Lum BL. Cosson VF, et al. Cancer Chemother Pharmacol. 2014 Apr;73(4):737-47. doi: 10.1007/s00280-014-2400-5. Epub 2014 Feb 12. Cancer Chemother Pharmacol. 2014. PMID: 24519752 Clinical Trial.

9

Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer.

Quartino AL, Li H, Jin JY, Wada DR, Benyunes MC, McNally V, Viganò L, Nijem I, Lum BL, Garg A. Quartino AL, et al. Cancer Chemother Pharmacol. 2017 Feb;79(2):353-361. doi: 10.1007/s00280-016-3218-0. Epub 2017 Jan 10. Cancer Chemother Pharmacol. 2017. PMID: 28074265 Free PMC article.

10

Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.

Lum BL, Kaubisch S, Fisher GA, Brown BW, Sikic BI. Lum BL, et al. Cancer Chemother Pharmacol. 2000;45(4):305-11. doi: 10.1007/s002800050045. Cancer Chemother Pharmacol. 2000. PMID: 10755319 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

181 results

Search Page

Filters